Find and Pitch Jounalists, Get Your Story Covered

	Profile	Recent Articles on Subject
1	Mike Bassett MedPage Today Explains healthcare complexities. Not endorsements. New York, New York Healthcare journalism	Antibody Drug-Conjugate Shows Promising Activity in Extensive-Stage SCLC - 8 days ago Targeted First-Line Combo Approved for EGFR-Mutated Lung Cancer - about 1 month ago FDA Approves Belzutifan for Advanced Renal Cell Carcinoma - 9 months ago Osimertinib Shows Activity in NSCLC With Uncommon EGFR Mutations - 10 months ago FDA OKs New Option for Advanced ROS1-Positive Lung Cancer - 10 months ago Bispecific Antibody Shows Clinical Activity in Recurrent Ovarian Cancer - 11 months ago RET Inhibitor Posts Frontline Wins in Medullary Thyroid Cancer, NSCLC - 11 months ago
2	PharmaTimes PharmaTimes PharmaTimes Media Ltd. Digital health news. Surrey, United Kingdom pharmahealthdigital healthmhealthNHSmarketingcommunicationsclinicaljobsMSL	MHRA approves Astellas’ Vyloy combination for gastric cancer - 28 days ago
3	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	FDA Accepts NDA and Priority Review Application for Vimseltinib in Tenosynovial Giant Cell Tumors - about 1 month ago FDA Approves Amivantamab-Vmjw and Lazertinib for First-Line Treatment of NSCLC - about 1 month ago FDA Grants Priority Review for Asciminib for Chronic Myeloid Leukemia - about 2 months ago FDA Grants Fast Track Designation to Potential Treatment for Clear Cell Renal Cell Carcinoma - 2 months ago FDA Accepts Supplemental New Drug Application for Adagrasib for Colorectal Cancer - 7 months ago FDA Grants Orphan Drug Designation to Tigilanol Tiglate for Soft Tissue Sarcoma - 7 months ago FDA Approves Belzutifan for Treatment of Advanced Renal Cell Carcinoma - 9 months ago FDA Approves Capivasertib With Fulvestrant for PIK3CA/ALT1/PTEN Alterations Breast Cancer - 10 months ago FDA Approves Repotrectinib for Treatment of ROS1-Positive NSCLC - 10 months ago TAK-279 Demonstrates Improvements in ACR 20 Response for Psoriatic Arthritis - 11 months ago FDA Grants Priority Review to New Drug Application for Belzutifan for Advanced Renal Cell Carcinoma - 12 months ago
4	Alana Hippensteele, Managing Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	FDA Approves Axatilimab-csfr for cGVHD - about 1 month ago Embracing a Precision Medicine Approach to KRAS G12C–Mutated Advanced NSCLC With Adagrasib - 6 months ago
5	Greg Laub MedPage Today Director of Video at MedPage Today. Screenwriter, previous managing editor. videographyscreenwritingediting	Belantamab Mafodotin: The Comeback Drug in Multiple Myeloma - 3 months ago TIL Therapy May Offer Novel Approach for Metastatic Lung Cancer - 3 months ago Novel TKI Promising in Early Study of HER2-Mutant NSCLC - 3 months ago Pirtobrutinib Shows Potential in Heavily Pretreated Follicular Lymphoma - 8 months ago Novel Doublet Highly Effective in Low-Grade Serous Ovarian Cancer - 10 months ago Ubamatamab Shows Some Activity in Recurrent Ovarian Cancer - 10 months ago New Data on TYK2 Inhibitors for Psoriasis, Psoriatic Arthritis - 10 months ago Anti-TIGIT Drug Fails to Lift Response Rates in Cervical Cancer Trial - 10 months ago
6	Ian Ingram MedPage Today Deputy Managing Editor. MedPage Today. New York, New York medical journalismediting	Brigatinib Makes Its Case for ALK-Positive ALCL in Small Study - 3 months ago FDA Approves New Frontline Regimen for Aggressive ALL - 6 months ago FDA OKs Amivantamab as First-Line Lung Cancer Treatment - 7 months ago JAK1 Inhibitor Shows 'Remarkable' Activity in T-Cell Lymphoma - 9 months ago Menin Inhibitor Yields 63% ORR in Heavily Pretreated Acute Leukemia - 9 months ago Non-Covalent BTK Inhibitor Approved for CLL - 10 months ago Lymphoma Drug Copanlisib to Be Pulled From U.S. Market - 10 months ago New Oral Drug Approved for Metastatic Colorectal Cancer - 11 months ago New Options Challenge Standard Treatments in EGFR-Mutant NSCLC - 11 months ago Randomized Trial Backs HIF-2a Inhibition in Advanced RCC - 11 months ago
7	Judy George MedPage Today Medical reporter, writer. Medical reportingartsliterature	ALS Therapy to Be Pulled From the Market, Drugmaker Says - 6 months ago
8	Kennedy Ferruggia, Assistant Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Jazz Pharmaceuticals Submits Biologics License Application for Zanidatamab to Treat Biliary Tract Cancer - 6 months ago Adagrasib Meets Primary Endpoint Among Individuals with KRAS G12C-Mutated Locally Advanced or Metastatic NSCLC - 6 months ago
9	Erin Hunter, Associate Editor Pharmacy Times Actor-writer. Nominated BBC Popcorn. London, United Kingdom actingwritingcomedy	FDA Accepts BLA for Datopotamab Deruxtecan for the Treatment of NSCLC - 7 months ago FDA Grants Breakthrough Therapy Designation to Nipocalimab for the Treatment of Rare Disease in Pregnancy - 7 months ago
10	Randy Dotinga MedPage Today Indie scribbler, advocate. Board member, @ahcj. San Diego WritingAdvocacy	EGFR Inhibitors for Lung Cancer Tied to Increased Keratitis Risk - 8 months ago

Journalists covering alectinib